Poirier J M, Le Jeunne C, Cheymol G, Cohen A, Barré J, Hugues F C
Service de Pharmacologie, Hôpital Saint-Antoine, Paris, France.
J Pharm Pharmacol. 1990 May;42(5):344-8. doi: 10.1111/j.2042-7158.1990.tb05423.x.
Six obese subjects (mean +/- s.d. : 145.1 +/- 16.7% of ideal body weight) were randomly assigned to a single i.v. dose either of (+/-)-propranolol base (0.108 mg kg-1 of ideal body weight) or of (+/-)-sotalol base (1.06 mg kg-1 of ideal body weight). Each subject received the other drug 7 days later. Pharmacokinetic parameters were compared with those obtained previously in non-obese control subjects. In obese subjects, the pharmacokinetic data calculated for sotalol were comparable with those measured in controls (total body clearance = 9.4 +/- 2.9 L h-1; volume of distribution during the terminal phase = 79.8 +/- 19.8 L or 0.9 +/- 0.2 L kg-1; terminal half-life = 6.2 +/- 1.6 h). For propranolol, total clearance (44.3 +/- 15.9 L h-1) and volume of distribution (230.5 +/- 48.2 L or 2.7 +/- 0.7 L kg-1) were significantly less than control values. The terminal half-life (3.9 +/- 1.1 h), was not significantly increased. These results could be explained by altered tissue blood flow and a decreased metabolic capacity of the liver in obese subjects.
六名肥胖受试者(平均±标准差:理想体重的145.1±16.7%)被随机分配接受单次静脉注射剂量的(±)-普萘洛尔碱(理想体重0.108 mg/kg)或(±)-索他洛尔碱(理想体重1.06 mg/kg)。每位受试者在7天后接受另一种药物。将药代动力学参数与之前在非肥胖对照受试者中获得的参数进行比较。在肥胖受试者中,索他洛尔计算得到的药代动力学数据与对照中测得的数据相当(总体清除率=9.4±2.9 L/h;终末相分布容积=79.8±19.8 L或0.9±0.2 L/kg;终末半衰期=6.2±1.6 h)。对于普萘洛尔,总清除率(44.3±15.9 L/h)和分布容积(230.5±48.2 L或2.7±0.7 L/kg)显著低于对照值。终末半衰期(3.9±1.1 h)没有显著延长。这些结果可以通过肥胖受试者组织血流改变和肝脏代谢能力降低来解释。